The Characterization and Outcomes of Colorectal Malignancy in Patients ≤40 Years of Age: A Single-Center Experience.


Journal

The American surgeon
ISSN: 1555-9823
Titre abrégé: Am Surg
Pays: United States
ID NLM: 0370522

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 28 7 2023
pubmed: 10 5 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Implementation of screening modalities has led to a decreased incidence of colorectal malignancies. Unfortunately, overall incidence has remained unchanged as cases have increased in patients below the suggested screening age. Therefore, we evaluated characteristics and oncological outcomes of malignancies in patients ≤40 years of age. Single-center retrospective analysis of prospectively collected data of malignancies in patients ≤40 years evaluated in our institution between 2010 and 2016. Basic descriptors for demographic, clinical, histologic, and genetic data were collected. Disease-free survival (DFS) and 5-year overall survival (OS) were compared for patients between 30-40 years and <30 years. Fifty-six patients ≤40 years were identified, 44 of whom (96.5%) had adenocarcinomas. Most common malignancy location was the rectum (64.3%). Despite aggressive tumor characteristics such as moderate/poor differentiation (88.6%), lymphovascular invasion (26.8%), perineural invasion (21.4%), and advanced tumor stage T3/T4 (60.7%), OS rate was 94.6%. Both age groups had similar oncologic characteristics. There was a trend toward worse OS (2/11 and 1/45, Patients ≤40 years of age with malignancy have advanced tumor stages and aggressive tumor characteristics at diagnosis. Although there is higher OS risk for patients <30 compared to those aged 30-40 years, no differences were found for DFS between these two groups.

Sections du résumé

BACKGROUND BACKGROUND
Implementation of screening modalities has led to a decreased incidence of colorectal malignancies. Unfortunately, overall incidence has remained unchanged as cases have increased in patients below the suggested screening age. Therefore, we evaluated characteristics and oncological outcomes of malignancies in patients ≤40 years of age.
METHODS METHODS
Single-center retrospective analysis of prospectively collected data of malignancies in patients ≤40 years evaluated in our institution between 2010 and 2016. Basic descriptors for demographic, clinical, histologic, and genetic data were collected. Disease-free survival (DFS) and 5-year overall survival (OS) were compared for patients between 30-40 years and <30 years.
RESULTS RESULTS
Fifty-six patients ≤40 years were identified, 44 of whom (96.5%) had adenocarcinomas. Most common malignancy location was the rectum (64.3%). Despite aggressive tumor characteristics such as moderate/poor differentiation (88.6%), lymphovascular invasion (26.8%), perineural invasion (21.4%), and advanced tumor stage T3/T4 (60.7%), OS rate was 94.6%. Both age groups had similar oncologic characteristics. There was a trend toward worse OS (2/11 and 1/45,
CONCLUSIONS CONCLUSIONS
Patients ≤40 years of age with malignancy have advanced tumor stages and aggressive tumor characteristics at diagnosis. Although there is higher OS risk for patients <30 compared to those aged 30-40 years, no differences were found for DFS between these two groups.

Identifiants

pubmed: 35533112
doi: 10.1177/00031348221096589
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2413-2426

Auteurs

Jose Melendez-Rosado (J)

Department of Gastroenterology, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Daniel Castaneda (D)

Department of Gastroenterology, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Victor Strassmann (V)

Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Yuksel Altinel (Y)

Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Argyrios Ioannidis (A)

Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Sara Rhode (S)

Department of Hematology/Oncology, Cleveland Clinic Florida, Weston, FL, USA.

Giovanna Da Silva (G)

Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Steven D Wexner (SD)

Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Rocio Lopez (R)

Quantitative Health and Science, Cleveland Clinic, Cleveland, OH, USA.

Brenda Jimenez (B)

Department of Gastroenterology, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH